Label Changes for:
Lotensin HCT (benazepril/hydrochlorothiazide) tablets
Changes have been made to the CONTRAINDICATIONS and ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009
- Lotensin is also contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.
- Erythema multiforme including Steven-Johnson syndrome, exfoliative dermatitis, including toxic epidermal necrolysis